Zakrzewicz Anna, Hecker Matthias, Marsh Leigh M, Kwapiszewska Grazyna, Nejman Bozena, Long Lu, Seeger Werner, Schermuly Ralph T, Morrell Nicholas W, Morty Rory E, Eickelberg Oliver
University of Giessen Lung Center, Department of Medicine II, Justus Liebig University Giessen, D-35392 Giessen, Germany.
Circulation. 2007 Jun 12;115(23):2957-68. doi: 10.1161/CIRCULATIONAHA.106.670026. Epub 2007 May 21.
Pulmonary arterial hypertension (PAH) is characterized by selective elevation of pulmonary arterial pressure. The pathological hallmark of PAH is the narrowing of pulmonary arterioles secondary to endothelial cell dysfunction and smooth muscle cell proliferation. Heterozygous mutations in BMPR2, encoding the type II bone morphogenetic protein receptor (BMPRII), were identified in PAH, suggesting that alterations to BMPRII function are involved in disease onset and/or progression.
We identified the receptor for activated C-kinase (RACK1) as a novel interaction partner of BMPRII by yeast 2-hybrid analyses using the kinase domain of BMPRII as a bait. Glutathione-S-transferase pull-down and coimmunoprecipitation confirmed the interaction of RACK1 with BMPRII in vitro and in vivo. RACK1-BMPRII interaction was reduced when kinase domain mutations occurring in patients with PAH were introduced to BMPRII. Immunohistochemistry of lung sections from PAH and control patients and immunofluorescence analysis of primary pulmonary arterial smooth muscle cells demonstrated colocalization of BMPRII and RACK1 in vivo. Quantitative reverse-transcription polymerase chain reaction and Western blot analysis showed significant downregulation of RACK1 expression in the rat model of monocrotaline-induced PAH but not in pulmonary arterial smooth muscle cells from PAH patients. Abrogation of RACK1 expression in pulmonary arterial smooth muscle cells led to decreased Smad1 phosphorylation and increased proliferation, whereas overexpression of RACK1 led to increased Smad1 phosphorylation and decreased proliferation.
RACK1, a novel interaction partner of BMPRII, constitutes a new negative regulator of pulmonary arterial smooth muscle cell proliferation, suggesting a potential role for RACK1 in the pathogenesis of PAH.
肺动脉高压(PAH)的特征是肺动脉压力选择性升高。PAH的病理标志是继发于内皮细胞功能障碍和平滑肌细胞增殖的肺小动脉狭窄。在PAH中发现了编码II型骨形态发生蛋白受体(BMPRII)的BMPR2杂合突变,提示BMPRII功能改变参与了疾病的发生和/或进展。
我们通过酵母双杂交分析,以BMPRII的激酶结构域为诱饵,鉴定出活化C激酶受体(RACK1)是BMPRII的新型相互作用伴侣。谷胱甘肽-S-转移酶下拉实验和免疫共沉淀证实了RACK1与BMPRII在体外和体内的相互作用。当将PAH患者中出现的激酶结构域突变引入BMPRII时,RACK1与BMPRII的相互作用减弱。对PAH患者和对照患者的肺组织切片进行免疫组织化学分析,以及对原代肺动脉平滑肌细胞进行免疫荧光分析,结果表明BMPRII和RACK1在体内共定位。定量逆转录聚合酶链反应和蛋白质免疫印迹分析显示,在野百合碱诱导的PAH大鼠模型中RACK1表达显著下调,但在PAH患者的肺动脉平滑肌细胞中未出现这种情况。肺动脉平滑肌细胞中RACK1表达的缺失导致Smad1磷酸化减少和细胞增殖增加,而RACK1的过表达导致Smad1磷酸化增加和细胞增殖减少。
RACK1是BMPRII的新型相互作用伴侣,构成肺动脉平滑肌细胞增殖的新负调节因子,提示RACK1在PAH发病机制中可能发挥作用。